Do you think Trius might see a sell off based on positive phase 3? I know analysts alongwith you have been pounding the table to buy but my biotech experience suggests otherwise. I bought at 6.07 mainly because I followed kitty around.
I'm also holding Progenix and you should look into it. CEO bought a hell lot at around 2.6-2.7 and I still might add more if it falls below 4.5. What other stocks do you recommend? SNTS is looking way out of my reach now.
There is a lot of 'new' money in this stock that bought in the 4s. They could dampen any pop on good news. If there is any decline, or even a less than ten percent rise on good Ph III data, I would buy more if your horizon is more than a year. The risk in this drug is safety. Efficacy is well enough established. If there are no new side effects shown, this stock will find itself on a steady rise thru partnership deals, approval, and new indications before eventual buy-out north of 18.
If you are a long term investor, buying on weakness after good results is a no brained. That's what big pharma does.
try SIGA for a judgement day reversal due in the next few days. When their vol. disappears it's usually a good indicator for a pop. TSRX may have a steady gain once phase lll is in. Like SIGA it has been fast tracked but unlike smallpox antiviral, TSRX's tedizolid is badly needed now. TSRX as a company has a good pipeline and started 2 yrs bfr SIGA went to court. Both SP are undervalued.
PGNX is a DOG. TSRX will fly on good news, hold up in this range, or slightly higher on neutral news and sell off if bad news. I don't think TRSK is that widely know, therefore plenty of institutions will need to buy if the data are strong enough to file for approval and there's a reasonable certainty of approval (stat sig- non inferior with lower side effects, less time).
I know PGNX looks like a DOG but Relistor sales were suprisingly good. If the conversation with FDA wents well this can easily double. In addition they have PSMA ADC in phase 2 and they might have an interim readout for ASCO 2013. There are not many companies available for cheap that have ADCs in clinic. ADCs are hottest thing right now. Read the recent earning cc.